About: Revaccination with a 23‐Valent Pneumococcal Polysaccharide Vaccine Induces Elevated and Persistent Functional Antibody Responses in Adults Aged ⩾65 Years

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Revaccination with a 23‐Valent Pneumococcal Polysaccharide Vaccine Induces Elevated and Persistent Functional Antibody Responses in Adults Aged ⩾65 Years Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

article

Attributes	Values
rdf:type	Item
description	article (en) wetenschappelijk artikel (nl) наукова стаття, опублікована в лютому 2010 (uk) im Februar 2010 veröffentlichter wissenschaftlicher Artikel (de)
publication date	wds:Q58457280-9447C4BC-131E-448F-B5E5-9A550A10D46F
publication date	2010-02-01 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q58457280-1FBB7944-598B-4034-A5CF-4CCD915388F8
language of work or name	English
author name string	wds:Q58457280-1D839654-77E5-41A8-BB58-F00E17F31A5A wds:Q58457280-21FC0AFD-0678-49FF-9781-88347BB6520D wds:Q58457280-5E036561-0816-490D-A525-BB4D598EDB2C wds:Q58457280-BB3FBEB3-A59D-48CE-8A2A-55BD5DD6316A wds:Q58457280-D74F6379-16A7-4D68-8EF5-7A6390D6FAF3 wds:Q58457280-E2C0C233-AF00-4102-B4DC-1DE483805C5A wds:Q58457280-FCA86B99-D6DC-481C-9F15-AB94C175B018
author name string	Rocio D Marchese Susan B Manoff Gowrisankar Rajam Michael J Caulfield John Boslego Charles Liss Jeffrey Silber
rdfs:label	Revaccination with a 23‐Valent Pneumococcal Polysaccharide Vaccine Induces Elevated and Persistent Functional Antibody Responses in Adults Aged ⩾65 Years (en) Revaccination with a 23‐Valent Pneumococcal Polysaccharide Vaccine Induces Elevated and Persistent Functional Antibody Responses in Adults Aged ⩾65 Years (nl)
skos:prefLabel	Revaccination with a 23‐Valent Pneumococcal Polysaccharide Vaccine Induces Elevated and Persistent Functional Antibody Responses in Adults Aged ⩾65 Years (en) Revaccination with a 23‐Valent Pneumococcal Polysaccharide Vaccine Induces Elevated and Persistent Functional Antibody Responses in Adults Aged ⩾65 Years (nl)
name	Revaccination with a 23‐Valent Pneumococcal Polysaccharide Vaccine Induces Elevated and Persistent Functional Antibody Responses in Adults Aged ⩾65 Years (en) Revaccination with a 23‐Valent Pneumococcal Polysaccharide Vaccine Induces Elevated and Persistent Functional Antibody Responses in Adults Aged ⩾65 Years (nl)
author	wds:Q58457280-47DD73FC-C02A-4114-9E13-06444DA5E9AF wds:Q58457280-4DD61C68-6028-4AD9-A2CD-24B49D3096E1 wds:Q58457280-D8411203-E419-41E1-A7C4-FE44B2C06EF1 wds:Q58457280-E14B49AA-8ADE-44F8-9D47-0DA4640718FE
author	George M Carlone Sandra Romero-Steiner Cynthia G Whitney Nina E Glass
title	wds:Q58457280-865B4CDA-E27E-4223-9114-3D247022E048
title	Revaccination with a 23-valent pneumococcal polysaccharide vaccine induces elevated and persistent functional antibody responses in adults aged 65 > or = years (en)
page(s)	wds:Q58457280-4AFCC516-5C77-488D-95CB-6CA7BE8A2AC6
page(s)	525-533
instance of	wds:Q58457280-14384B56-0E08-4C4B-A25F-49133A89CC56
instance of	scholarly article
main subject	wds:Q58457280-49AA7C1F-10B0-4EB2-A24D-2E7731D36D29 wds:Q58457280-75A8444D-3D21-49F2-85B6-5961DD669831 wds:Q58457280-7C5F97BA-616D-4769-A70C-EC4842B78F5F wds:Q58457280-d5505fc3-44ca-dc2c-578c-d3975832e63b
main subject	booster dose vaccine antibody polysaccharide
PubMed ID	wds:Q58457280-F3127716-DDF4-4ADF-BC56-315B37DCB766
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/20088694
PubMed ID	20088694
published in	wds:Q58457280-F8426374-DD4D-4B2C-89EB-34FE135AC878
published in	Journal of Infectious Diseases
issue	wds:Q58457280-740F0D25-9479-4164-81D9-84EC5B7A17A6
volume	wds:Q58457280-0FECBA4A-8C1E-454B-AAAD-EDE1CA355DEB
issue	4
volume	201
DOI	wds:Q58457280-CD5113C0-90CC-408B-917D-944398533A63
DOI	http://dx.doi.org/10.1086/651131
DOI	10.1086/651131
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q58457280
is cites work of	Pneumonia immunization in older adults: review of vaccine effectiveness and strategies Pneumococcal polysaccharide vaccination for adults: new perspectives for Europe. A public health and budget impact analysis of vaccinating at-risk adults and the elderly against pneumococcal diseases in Germany Cost–effectiveness of vaccinating adults with the 23-valent pneumococcal polysaccharide vaccine (PPV23) in Germany Long-term comparative immunogenicity of protein conjugate and free polysaccharide pneumococcal vaccines in chronic obstructive pulmonary disease Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine Cost-effectiveness of dual influenza and pneumococcal vaccination in 50-year-olds Pneumococcal Vaccination Strategies. An Update and Perspective. Randomized, controlled trial of a 13-valent pneumococcal conjugate vaccine administered concomitantly with an influenza vaccine in healthy adults The development of 13-valent pneumococcal conjugate vaccine and its possible use in adults Randomized, single blind, controlled trial to evaluate the prime-boost strategy for pneumococcal vaccination in renal transplant recipients Pneumococcal polysaccharide 23-valent vaccine: long-term persistence of circulating antibody and immunogenicity and safety after revaccination in adults Age-related immune response to pneumococcal polysaccharide vaccination: lessons for the clinic Sustained functional serotype-specific antibody after primary and secondary vaccinations with a pneumococcal polysaccharide vaccine in elderly patients with chronic lung disease Severe community-acquired pneumonia Pneumococcal conjugate vaccine use in adults - Addressing an unmet medical need for non-bacteremic pneumococcal pneumonia. No long-term evidence of hyporesponsiveness after use of pneumococcal conjugate vaccine in children previously immunized with pneumococcal polysaccharide vaccine The epidemiologic evidence underlying recommendations for use of pneumococcal polysaccharide vaccine among American Indian and Alaska Native populations Revaccination with 23-valent pneumococcal polysaccharide vaccine in the Japanese elderly is well tolerated and elicits immune responses. Pre-clinical evaluation of a 15-valent pneumococcal conjugate vaccine (PCV15-CRM197) in an infant-rhesus monkey immunogenicity model. Pneumococcal conjugate vaccine triggers a better immune response than pneumococcal polysaccharide vaccine in patients with chronic lymphocytic leukemia A randomized study by the Swedish CLL group Effectiveness and practical uses of 23-valent pneumococcal polysaccharide vaccine in healthy and special populations. Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine compared to the 23-valent pneumococcal polysaccharide vaccine in elderly Japanese adults Repeat pneumococcal polysaccharide vaccine in Indigenous Australian adults is associated with decreased immune responsiveness Persistence of immunity to conjugate and polysaccharide pneumococcal vaccines in frail, hospitalised older adults in long-term follow up Effectiveness, immunogenicity and safety of 23-valent pneumococcal polysaccharide vaccine revaccinations in the elderly: a systematic review Dosing regimen of the 23-valent pneumococcal vaccination: a systematic review Background paper to the updated pneumococcal vaccination recommendation for older adults in Germany. Time interval of revaccination with 23-valent pneumococcal polysaccharide vaccine more than 5 years does not affect the immunogenicity and safety in the Japanese elderly Immunogenicity and safety of a 23-valent pneumococcal polysaccharide vaccine in Chinese healthy population aged >2 years: A randomized, double-blinded, active control, phase III trial The association of ethnicity with antibody responses to pneumococcal vaccination among adults with HIV infection. Dose-ranging study of a single injection of pneumococcal conjugate vaccine (1×, 2×, or 4×) in healthy subjects aged 70 years or older Dectin-2-dependent NKT cell activation and serotype-specific antibody production in mice immunized with pneumococcal polysaccharide vaccine Safety and immunogenicity of a single dose 23-valent pneumococcal polysaccharide vaccine in Russian subjects V(H)3 antibody response to immunization with pneumococcal polysaccharide vaccine in middle-aged and elderly persons Pneumococcal vaccines in adults: assessing the evolving evidence

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 190 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software